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The bacterial drug resistance is its ability to grow in presence of high  concentration of an antibiotic. 
The massive and often unsuitable use of antibiotic tends to select the resistant mutants that are then 
disseminated. The -lactam antibiotics represent an antibiotic family widely used because of their 
remarkable tolerance by animal organism. This practice generated the resistance from many bacteria in 
clinical and environmental spaces. One of the main drug resistance mechanism used by bacteria is the 
production of inactivation enzymes named -lactamases. This mini review attempts to pinpoint the -
lactamase incidence on the failure of clinical treatment using  -lactam antibiotic anywhere. 
 





Antibiotic resistance of pathogenic bacteria is more and 
more of high clinical relevance. Penicillin is the first 
antibiotic discovered by Fleming (1929). Penicillin 
belongs to β-lactam antibiotics which have a lethal effect 
on bacteria via an interaction with the target proteins 
known as penicillin-binding proteins (PBPs) located on 
the cell membrane. The PBPs are enzymes 
(transpeptidases) which are involved in bacterial wall 
peptidoglycan cross-linking. The damage caused by β-
lactams to bacteria particularly in growing state come 
from their ability to bind transpeptidases and to inactivate 
them. This process of inactivation of the cross-linking 
enzymes disrupts the normal physiological constitution of 
cell wall peptidoglycan and induces cell lysis and death 
(Thomas et al., 1977). Unfortunately for chemotherapy 
and clinical treatement, β-lactamases which could be 
considered as bacterial absolute molecular weapons 
appeared. These enzymes probably existed before the 
discovery of β-lactam antibiotics, and may play other 
roles in bacteria. Until today β-lactamases have been 
exclusively found in bacteria. β-lactamase activity has not 
been detected in β-lactam-producing fungi such as 
Penicillium and Cephalosporium species (Ogawara et al., 
1999). About the origin of these enzymes, the accepted 
idea today is that β-lactamases are the result of 
conversion of PBPs by genetic transformation. This 
means that both types of proteins have a common 
ancestor. β-Lactamase were first described as an 
enzyme from bacteria able to destroy penicillin by 
Abraham et al. (1940). The first factor responsible for 
bacterial resistance is the constitutive or inducible 
production of these hydrolytic enzymes. These enzymes 
were characterized by the Special Commission of the 
International Union of Biochemistry as enzymes acting on 
amide and cyclic amide bond (Webb, 1984; Figure 1). 
Therefore, they have the classification number (E.C 
3.5.2.6) and received the systematic name of β-lactam 
hydrolases. 
The aim of this short review on the great and complex 
subject of β-lactamases is to analyse β-lactamase 
mediated bacterial resistance throughout the world with a 
particular focus on the African area. We hope that this 
modest contribution will attract attention to the 
phenomenon and help devising a modified approach to 
antibiotic consumption in the African area. 
 
 
CLASSIFICATION OF β-LACTAMASES 
 
β-Lactamases are grouped into 4 classes (Ambler, 1980) 
named A, C, D and B which derive from two main groups 
(serine and metallo-β-lactamases) (Table 1, Figure 2). 
The following are the features of the different classes of 
β-lactamases: 
 
1. The class A enzymes include many members of which 
TEM and SHV are the main  representatives.  Historically  











Figure 1. Hydrolytic reaction of β-lactamase on the amide bond of the β-lactam ring. 
                              
 
 






Group 2a molecular Class A 
25-32 kDa Narrow spectrum penicillinases carried by Gram-negative 
bacteria and inhibited by active site inactivators (such as clavulanic acid). 
Example: Klebsiella pneumoniae chromosomal β-lactamase, LEN-1. 
Group 2b molecular class A 22-36 kDa Broad spectrum penicillinases, inhibited by clavulanic acid. Example: Enterobacter cloacae plasmid pDSO76 β-lactamase, OHIO-1. 
Group 1 molecular Class C 
40 kDa Cephalosporinases not inhibited by active site inactivators. 




molecular Class A 
28-29 kDa, extended spectrum β-lactamases (ESBL) type TEM and  SHV, 
inhibited by active site inactivators. Example: Pseudomonas aeruginosa 
chromosomal β-lactamase, PER-1. 
Group 2br molecular Class A 
24 kDa Broad spectrum β-lactamases not well inhibited by active site 
inactivators. Example:Escherichia coli strain GUER plasmid β-lactamase, 
TEM-30. 
Group 2c molecular Class A 
22-34 kDa Carbenicillinase type PSE inhibited by active site inactivators. 
Example: Acinetobacter calcoaceticus strain A85-145 β-lactamase, CARB-
5. 
Group 2d molecular Class D 29-53 kDa Oxacillinases, not well inhibited by active site inactivators. Example:Salmonella typhimurium strain type 1a β-lactamase, OXA-2. 
Group 2e molecular Class A 27-48 kDa Cephalosporinases inhibited by active site inactivators. Example: Yersinia enterocolitica strain y56 chromosomal β-lactamase. 
Group 2f molecular Class A 
29-30 kDa  Serine Carbapenemases. Example: Serratia marcescens 
strain S6 chromosomal β-lactamase, Sme-1. 
Group 3 molecular Class B 
25-120 kDa, Metallo-carbapenemases) métallo-β-lactamases. Example: 
Chryseopbacterium (Flavobacterium) indologenes chromosomal β-
lactamase found in Burkina Faso (Africa) named IND-B. 
   
 
aBush et al., 1995. 




the term “TEM” comes from the fact that the parental 
enzyme was found in the blood of a patient in Greece 
named Temoniera, hence this β-lactamase was designed 
TEM-1. The appellation SHV comes from SulpHydryl 
Variable. Owing to the massive and intensive use of β-
lactam antibiotics, the parental forms TEM-1 and SHV-1  
underwent mutations yielding more than one hundred 
variants of TEM and more than twenty variants of SHV.  
ß-lactam ring : the 
target of ß-
lactamases 
ß-lactam ring opened  
by ß-lactamase : the resultant 
product is harmless to the bacteria 







Figure 2. Main classes of β-lactamases. The representatives in each class are simply selected 
examples and do not correspond to all members of the class. For example class A and class B contain 




Most of these variants have high catalytic efficiencies and 
extended spectral activities. They are  named  ESBLs  for  
Extended Spectral β-lactamases (Bradford, 2001). The 
TEM Variants are ubiquitous in Escherichia coli strains 
and SHV variants are predominant in KLebsiella 
pneumoniae. 
 
2. The class C enzymes include non or few variants and 
the main representative remains AmpC which is 
chromosomally encoded in Citrobacter freundii, 
Enterobacter cloacae and Morganella morganii (Hanson 
et al., 1999). These β-lactamases are mainly inducible 
and highly active on first and second generation 
cephalosporins such as cefalotin, cephaloridin and 
cefalexin. 
 
3. The class D enzymes belong as A and C to serine 
hydrolases and are essentially OXA (oxacillin-
hydrolyzing) type enzymes which are frequently 
described in Pseudomonas aeruginosa. Like TEM and 
SHV, the OXA type includes at least thirty variants and 
some of them have an extended spectrum profile 
(Philipon et al., 1997; Poirel et al., 2001). 
 
4. Class B enzymes differ from the 3 other classes in 
many respects. These enzymes are structurally and 
functionally distinct because of a vital need for one or two 
Zn(II) ion(s) in their active centre for activity. They are 
metallo-β-lactamases and may confer multi-resistance to 
bacteria because of their ability to destroy most of the 
potent β-lactams including carbapenems. These 
enzymes are of the great clinical concern. 
WORLDWIDE DISTRIBUTION OF β-LACTAMASES 
 
During the last fifty years β-lactamases have received 
much attention because of their clinical relevance. 
Indeed, they have been responsible for a large number of 
therapeutic failures. In the early 1960s, the first plasmid-
mediated β-lactamase in an Escherichia coli strain, TEM-
1, was described in Europe (Datta et al., 1965). 
Thereafter the worldwide spread of the TEM-1 genetic 
element to other bacterial species (P. aeruginosa, 
Haemophilus influenzae, Neisseria gonorrhoeae etc) was 
observed (Bradford, 2001). At the same time another 
enzyme, SHV-1, appeared. This β-lactamase is 
chromosomally encoded in K. pneumoniea but plasmid 
encoded in E. coli. Owing to the introduction of the potent 
β-lactam antibiotics (oxyimino-cephalosporins ) into the 
market to suppress the resistance due to hydrolase 
activity, the wild types TEM-1 and SHV-1 spontaneously 
mutated, yielding extended spectrum enzymes. In this 
way, SHV-2 the pioneer of these enzymes appeared in K. 
pneumoniae in Germany (Kliebe et al., 1985). The 
number of these new types of enzymes able to destroy 
potent third generation β-lactams (designed ESBLs) is 
continuously increasing particularly in Europe and Asia. 
 
 
DRUG RESISTANCE INVOLVING β-LACTAMASES IN 
AFRICA 
 
The evolution of bacterial drug resistance in general and 
specifically via β-lactamases is not well investigated on 
the African continent. An important lack of scientific 
information about the subject is observed. The rare  




reports about the role of β-lactamases often come from 
South Africa. Hence Proteus mirabilis, E. coli were found 
to produce TEM-26, SHV-2, and SHV-5 extended 
spectrum β-lactamases, while an AmpC related enzyme 
was found in K. pneumoniae (Pitout et al., 1998) in South 
Africa. Earlier, studies on bacterial strains isolated in 
Senegal/West African area have detected a high 
frequency      of      SHV-1      -lactamase      in      E.coli 
(Shaokat et al., 1987). These strains appeared to be 
particularly resistant to amoxicillin and ticarcillin. From 
2000 to 2005 in a screening of E. coli and K. pneumoniae 
strains in Burkina Faso, we found a high frequency of 
SHV types β-lactamase in K. pneumoniae (Zeba et al., 
2004) and TEM types β-lactamase in E. coli (results not 
published). Our results also indicate that the parental 
forms of these enzymes (SHV-1 and TEM-1) are most 
frequent. But two SHV-11 mutants were also identified in 
Burkina Faso in K. pneumoniae clinical strains. Our 
results are in agreement with previous studies (Shaokat 
et al., 1987). SHV-1 and TEM-1 are probably the most 
predominant β-lactam hydrolases in species such as E. 
coli and K. pneumoniae. But it is necessary to pay 
attention to the emergence of high efficiency variants of 
SHV-1 and TEM-1. The emergence of ESBLs such as 
SHV-5 in South Africa is a serious warning for the other 
countries. We also detected AmpC-type β-lactamases in 
strains of Enterobacter cloacae and Citrobacter freundii.  
Another chapter to be opened for bacterial resistance 
mediated by β-lactamase in Africa is the emergence of 
enzymes conferring multidrug resistance to the producing 
bacteria. The identification of a metallo-β-lactamase 
(MBL) in Burkina Faso during the last year (Zeba et al., 
2005) is probably of grave concern. The gene encoding 
this Zn (II) β-lactamase was isolated from a clinical 
Chryseobacterium (Flavobacterium) indologenes strain 
and sequenced. It is a new variant of IND-β-lactamases 
(results not yet reported). The particular characteristics 
and kinetic efficiencies of this enzyme underline the fact 
that, as in Japan particularly, Europe (Italy, France) and 
America (Canada, Bresil), the African continent must 
prepare for the challenge of metallo-β-lactamases. A 
critical evolution of bacterial resistance mediated by β-
lactamases is rapidly developing in many of the countries 
where resources are limited. The fragile situation of 
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